We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+7.3%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$164M
AUM Growth
+$4.83M
Cap. Flow
-$759K
Cap. Flow %
-0.46%
Top 10 Hldgs %
85.32%
Holding
58
New
4
Increased
8
Reduced
3
Closed
4

Top Buys

Rank Stock Value
1
VRML
Vermillion, Inc.
VRML
+$1.16M
2
BMY icon
Bristol-Myers Squibb
BMY
+$1.12M
3
DERM
Dermira, Inc.
DERM
+$1.08M
4
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$918K
5
BIIB icon
Biogen
BIIB
+$577K

Top Sells

Rank Stock Value
1
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$5.79M
2
IFRX icon
InflaRx
IFRX
+$605K
3
OMED
OncoMed Pharmaceuticals, Inc.
OMED
+$387K
4
CELG
Celgene Corp
CELG
+$128K
5
ATRA icon
Atara Biotherapeutics
ATRA
+$113K

Sector Composition

Rank Sector Weight
1 Healthcare 96.53%
2 Energy 1.97%
3 Consumer Staples 0.07%
4 Consumer Discretionary 0.05%
5 Materials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$64.5M 39.22%
697,667
-1,344
-0.2% -$128K
AXDX
2
DELISTED
Accelerate Diagnostics
AXDX
$50M 30.39%
218,380
– –
ARRY
3
DELISTED
Array Biopharma Inc
ARRY
$7.78M 4.73%
168,000
– –
NBIX icon
4
Neurocrine Biosciences
NBIX
$17.2B
$4.64M 2.82%
55,000
– –
QDEL icon
5
QuidelOrtho
QDEL
$1.19B
$2.9M 1.76%
48,844
+1,769
+4% +$106K
VRML
6
DELISTED
Vermillion, Inc.
VRML
$2.78M 1.69%
3,121,933
+1,000,000
+47% +$1.16M
EQM
7
DELISTED
EQM Midstream Partners, LP
EQM
$2.23M 1.36%
50,000
– –
BMY icon
8
Bristol-Myers Squibb
BMY
$124B
$2M 1.21%
44,000
+24,000
+120% +$1.12M
OXFD
9
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$1.93M 1.17%
140,303
+60,000
+75% +$918K
HROW icon
10
Harrow
HROW
$1.74B
$1.57M 0.95%
180,000
– –
ARNA
11
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.29M 0.78%
22,000
– –
GTHX
12
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$1.23M 0.75%
40,000
+25,000
+167% +$526K
ALBO
13
DELISTED
Albireo Pharma Inc
ALBO
$1.23M 0.75%
38,000
– –
MASI
14
DELISTED
Masimo
MASI
$1.19M 0.72%
8,000
– –
BIIB icon
15
Biogen
BIIB
$30.4B
$1.17M 0.71%
5,000
+2,500
+100% +$577K
DERM
16
DELISTED
Dermira, Inc.
DERM
$1.15M 0.7%
120,000
+100,000
+500% +$1.08M
AMRN
17
Amarin Corp
AMRN
$292M
$1.14M 0.7%
2,950
– –
VNDA icon
18
Vanda Pharmaceuticals
VNDA
$327M
$1.13M 0.69%
80,000
– –
WMGI
19
DELISTED
Wright Medical Group Inc
WMGI
$895K 0.54%
30,000
– –
VCYT icon
20
Veracyte
VCYT
$4.72B
$877K 0.53%
30,767
-4,000
-12% -$99.9K
VYGR icon
21
Voyager Therapeutics
VYGR
$192M
$817K 0.5%
30,000
– –
XLRN
22
DELISTED
Acceleron Pharma
XLRN
$767K 0.47%
18,672
– –
ODT
23
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$734K 0.45%
20,000
– –
DRNA
24
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$709K 0.43%
45,000
– –
DOVA
25
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$705K 0.43%
50,000
– –
1
2 3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q2 2019 Portfolio in Review

As of Q2 2019, Birchview Capital held 58 positions worth $164M, up 3% from $160M the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Birchview Capital's Q2 2019 filing shows 4 new, 8 increased, 3 reduced and 4 closed positions. Its largest new stake was Acadia Pharmaceuticals: 10,000 shares worth $267K. The largest sale was Clementia Pharmaceuticals Inc., an estimated $5.79M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q2 2019 buy was Acadia Pharmaceuticals: 10,000 shares worth $267K.
  • Birchview Capital added most to Vermillion, Inc. in Q2 2019, an estimated $1.16M increase.
  • Birchview Capital's biggest Q2 2019 reduction was Celgene Corp, cutting an estimated $128K.
  • Birchview Capital fully exited Clementia Pharmaceuticals Inc. in Q2 2019, selling an estimated $5.79M.
  • Birchview Capital's ten largest holdings make up 85% of its $164M portfolio in Q2 2019.
  • Birchview Capital opened 4 new positions and closed 4 in Q2 2019.
  • Birchview Capital's portfolio value rose 3% quarter-over-quarter to $164M.

Based on Birchview Capital's 13F filing for Q2 2019, filed 6 Aug 2019.